AD_____

Award Number: W8 1XWH-07-1-0059

TITLE: Evaluation of Fibroblast Activation Protein-Alpha (FAP) as a Diagnostic Marker and Therapeutic Target in Prostate Cancer

PRINCIPAL INVESTIGATOR: Nathaniel Brennen

CONTRACTING ORGANIZATION: Johns Hopkins University Baltimore, MD 21218-2686

REPORT DATE: December 2007

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

CHECKT DUCCOMPANY Control Processing Statuted to wraves a floar per response, finding the lines for reversing instances, and ordering and reversing the address
Table Regarded user for the code societ of a monthalment of a monthale field of the magnetic of the monthale field of the magnetic of the monthale field of the magnetic of the
1. REPORT DATE (DD-MM-YYYY) 2. REPORT TYPE 3. DATES COVERED (From - To) 4. TITLE AND SUBTITLE 14 MAR 2006 - 28 JUN 2007 Evaluation of Fibroblast Activation Protein-Alpha (FAP) as a Diagnostic Marker and Therapeutic Target in Prostate Cancer 5b. GRANT NUMBER 6. AUTHOR(S) 5d. PROJECT NUMBER Nathaniel Brennen 5d. PROJECT NUMBER E-Mail: wbrenne2@jhmi.edut 5f. WORK UNIT NUMBER 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT Johns Hopkins University 8. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command 10. SPONSOR/MONITOR'S ACRONYM(S) 7. PERFORMING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 13. SUPPLEMENTARY NOTES
4. TITLE AND SUBTITLE 5a. CONTRACT NUMBER Evaluation of Fibroblast Activation Protein-Alpha (FAP) as a Diagnostic Marker and Therapeutic Target in Prostate Cancer 5b. GRANT NUMBER 6. AUTHOR(S) 5c. PROGRAM ELEMENT NUMBER 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 5c. TASK NUMBER 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 11. SPONSOR/MONITOR'S REPORT NUMBER(S)
Evaluation of Fibroblast Activation Protein-Alpha (FAP) as a Diagnostic Marker and Therapeutic Target in Prostate Cancer 5b. GRANT NUMBER W8 1XWH-07-1-0059 Sc. PROGRAM ELEMENT NUMBER 6. AUTHOR(\$) Nathaniel Brennen 5d. PROJECT NUMBER E-Mail: wbrenne2@jhmi.edut 5d. PROJECT NUMBER 7. PERFORMING ORGANIZATION NAME(\$) AND ADDRESS(E\$) Johns Hopkins University Baltimore, MD 21218-2686 8. PERFORMING ORGANIZATION REPORT NUMBER 9. SPONSORING / MONITORING AGENCY NAME(\$) AND ADDRESS(E\$) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 10. SPONSOR/MONITOR'S ACRONYM(\$) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 11. SPONSOR/MONITOR'S REPORT NUMBER 13. SUPPLEMENTARY NOTES 13. SUPPLEMENTARY NOTES
6. AUTHOR(S) Nathaniel Brennen 5d. PROJECT NUMBER 5e. TASK NUMBER 5e. TASK NUMBER F-Mail: wbrenne2@jhmi.edut 5f. WORK UNIT NUMBER 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Johns Hopkins University Baltimore, MD 21218-2686 8. PERFORMING ORGANIZATION REPORT NUMBER 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 10. SPONSOR/MONITOR'S ACRONYM(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 11. SPONSOR/MONITOR'S REPORT NUMBER(S)
6. AUTHOR(S) Nathaniel Brennen 5d. PROJECT NUMBER 5e. TASK NUMBER 5e. TASK NUMBER F-Mail: wbrenne2@jhmi.edut 5f. WORK UNIT NUMBER 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Johns Hopkins University Baltimore, MD 21218-2686 8. PERFORMING ORGANIZATION REPORT NUMBER 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 10. SPONSOR/MONITOR'S ACRONYM(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 13. SUPPLEMENTARY NOTES 13. SUPPLEMENTARY NOTES
E-Mail: wbrenne2@jhmi.edut 5e. TASK NUMBER F. Mork UNIT NUMBER 5f. WORK UNIT NUMBER 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBER Johns Hopkins University 8. PERFORMING ORGANIZATION REPORT NUMBER Baltimore, MD 21218-2686 10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command 10. SPONSOR/MONITOR'S ACRONYM(S) Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 13. SUPPLEMENTARY NOTES
E-Mail: wbrenne2@jhmi.edut 5f. WORK UNIT NUMBER 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBER Johns Hopkins University 8. PERFORMING ORGANIZATION REPORT NUMBER 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 10. SPONSOR/MONITOR'S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 13. SUPPLEMENTARY NOTES
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT Johns Hopkins University Baltimore, MD 21218-2686 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) U.S. Army Medical Research and Materiel Command 11. SPONSOR/MONITOR'S REPORT Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S REPORT 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 13. SUPPLEMENTARY NOTES
Johns Hopkins University Baltimore, MD 21218-2686 10. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 10. SPONSOR/MONITOR'S ACRONYM(S) 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) U.S. Army Medical Research and Materiel Command 11. SPONSOR/MONITOR'S ACRONYM(S) Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S REPORT 12. DISTRIBUTION / AVAILABILITY STATEMENT NUMBER(S) Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S) U.S. Army Medical Research and Materiel Command 11. SPONSOR/MONITOR'S ACRONYM(S) Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES
Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR'S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES
11. SPONSOR/MONITOR'S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES
13. SUPPLEMENTARY NOTES
13. SUPPLEMENTARY NOTES
14. ABSTRACT Abstract provided on next page.
15. SUBJECT TERMS
Prodrug, Fibroblast, Protease
16. SECURITY CLASSIFICATION OF: 17. LIMITATION 18. NUMBER 19a. NAME OF RESPONSIBLE PERSON OF ABSTRACT OF PAGES USAMRMC
a. REPORT U U L U U U U U U U U U U U U U U U U U

Standard Form 298 (Rev. 8	-98)
Prescribed by ANSI Std. Z39.18	

Technical Abstract:

Background: It has been well documented that the tumor is dependent upon the reactive stroma for survival and growth signals, as well as, the nutritional support necessary for the maintenance of the primary mass. Additionally, the ability of the stroma to not only contribute to, but potentially drive, the progression of cancerous cells into a highly aggressive and metastatic phenotype is a concept that has only recently begun to be appreciated. The stroma has been shown to undergo morphological alterations, recruit reactive fibroblasts, macrophages, and lymphocytes, increase secretion of growth factors, signaling molecules and proteases, induce new blood vessel formation, as well as, produce an altered extracellular matrix when associated with a transformed epithelium. Fibroblasts, in particular, have been shown to consistently undergo several changes in both morphology and expression profiles when present in the tumor microenvironment. One defining characteristic of these carcinoma-associated fibroblasts, or myofibroblasts, is the expression of fibroblast activation protein-alpha (FAP). FAP is a membrane-bound serine protease that has both dipeptidase, as well as, gelatinase and collagenase activity. FAP is not expressed in healthy adults, but has been shown to be selectively expressed on myofibroblasts in the stroma surrounding >90% of epithelial cancers examined, including 7/7 human prostate cancer specimens, with minimal to no expression in either cancerous epithelial or adjacent normal tissues. FAP has been implicated in tumor promotion through studies demonstrating increases in tumor incidence, growth, and microvessel density using in vivo models. In contrast, other studies have shown that expression of FAP decreased tumorigenicity in vivo suggesting that the physiologic response to FAP may be dependent upon the exact context of its expression.

Objective/Hypothesis: Our goal is to evaluate FAP expression patterns and enzymatic activity in both normal prostate tissue and at various stages of oncogenic transformation (i.e. PIA, PIN, Localized and Advanced Cancer) to determine tumor stage in which FAP expression may play a role. A second objective is to exploit this expression in the treatment of prostate cancer by developing therapies targeted for activation by FAP. This will be accomplished by identifying selective peptide substrates for the proteolytic activity of FAP and coupling these peptides to a highly cytotoxic agent, thapsigargin, to generate prodrugs that are only activated in prostate tumors where FAP is expressed.

Specific Aims:

1) Characterize the expression patterns of FAP in normal prostate tissue and in the disease state.

2) Identify a FAP-specific cleavable peptide sequence for the development of targeted prodrugs.

3) Synthesize prodrug and measure kinetics in vitro.

4) Determine the potential therapeutic benefit and toxicity of this prodrug in vivo.

Study Design: We will generate and characterize clones of various prostate cancer cell lines (LNCaP, C4-2, C4-2B4, and PC3) expressing FAP or an empty vector control. Primary human prostate cancer tissue specimens representing varying stages of prostate cancer, as well as, adjacent normal tissue will be stained for FAP expression and quantified. FAP-specific peptide substrates will be identified in a complementary approach using a solution-phase phage display library and a positional scanning synthetic combinatorial library. Optimal substrate sequences will be coupled to thapsigargin, a highly cytotoxic compound. Kinetics of hydrolysis, as well as, specificity and stability will be measured in vitro using the FAP-expressing clones. Lead prodrugs identified in vitro will be used to treat xenografts derived from FAP-expressing clones and mock-transfected controls to determine potential therapeutic efficacy in vivo.

Impact: Metastatic epithelial cancers, such as those of the prostate, are composed of heterogeneous populations of cells that can have variable responses to anti-tumor agents. Currently utilized standard antiproliferative chemotherapies can produce modest improvement in survival in select cancer types, but are largely ineffective in treating malignancies of the prostate (proliferative index < 5%). Novel therapies that act in a proliferation-independent manner, therefore, are urgently needed for the treatment of advanced prostate cancer. An emerging strategy has been to target the stromal components associated with the tumor. One potential therapy is the development of prodrugs activated by proteases selectively expressed in the stromal compartment as outlined in this proposal. This approach will effectively deliver a cytotoxic molecule, such as thapsigargin, in a highly specific manner to the tumor microenvironment and will directly result in significant stromal cell death and indirectly in epithelial mortality due to a bystander effect with limited systemic toxicity.

Table of Contents

Cover	1
SF298	2
Table of Contents	3
Introduction	4
Body	5
Key Research Accomplishments	8
Reportable Outcomes	8
Conclusion	9
References	9
Appendix	10

Introduction

It has been well documented that the tumor is dependent upon the reactive stroma for survival and growth signals, as well as, the nutritional support necessary for the maintenance of the primary mass. Additionally, the ability of the stroma to not only contribute to, but potentially drive, the progression of cancerous cells into a highly aggressive and metastatic phenotype is a concept that has only recently begun to be appreciated. The stroma has been shown to undergo morphological alterations, recruit reactive fibroblasts, macrophages, and lymphocytes, increase secretion of growth factors, signaling molecules and proteases, induce new blood vessel formation, as well as, produce an altered extracellular matrix when associated with a transformed epithelium. Fibroblasts, in particular, have been shown to consistently undergo several changes in both morphology and expression profiles when present in the tumor microenvironment. One defining characteristic of these carcinoma-associated fibroblasts, or myofibroblasts, is the expression of fibroblast activation protein-alpha (FAP). FAP is a membrane-bound serine protease that has both dipeptidase, as well as, gelatinase and collagenase activity. FAP is not expressed in healthy adults, but has been shown to be selectively expressed on myofibroblasts in the stroma surrounding >90% of epithelial cancers examined, including 7/7 human prostate cancer specimens, with minimal to no expression in either cancerous epithelial or adjacent normal tissues. FAP has been implicated in tumor promotion through studies demonstrating increases in tumor incidence, growth, and microvessel density using in vivo models. In contrast, other studies have shown that expression of FAP decreased tumorigenicity in vivo suggesting that the physiologic response to FAP may be dependent upon the exact context of its expression. Our goal is to evaluate FAP expression patterns and enzymatic activity in both normal prostate tissue and at various stages of oncogenic transformation (i.e. PIA, PIN, Localized and Advanced Cancer) to determine tumor stage in which FAP expression may play a role. A second objective is to exploit this expression in the treatment of prostate cancer by developing therapies targeted for activation by FAP. This will be accomplished by identifying selective peptide substrates for the proteolytic activity of FAP and coupling these peptides to a highly cytotoxic agent. thapsigargin, to generate prodrugs that are only activated in prostate tumors where FAP is expressed.

Body

Hypothesis and Objective

Our hypothesis is that FAP is expressed on the surface of myofibroblasts in the stroma surrounding the majority of malignant prostatic lesions and that this expression can be taken advantage of for clinical benefit. The goal of this proposal is to investigate FAP expression patterns in normal prostate tissue and prostate cancers at various stages and to develop novel FAP-activated prodrug therapies that exploit FAP's tumor stroma restricted expression in the treatment of prostate cancer. Furthermore, due to the localized expression of FAP to the stroma associated with tumors from multiple tissues of origin, this therapy may have the potential to effectively treat a broad spectrum of epithelial malignancies.

Specific Aims 1: Characterize the expression patterns of FAP in normal and hyperplastic prostate tissue and in various stages of prostate cancer

Limited information is available on expression of FAP in prostate tissue. Initial studies characterizing FAP expression in epithelial cancers did not include prostate cancer. The only data showing FAP expression is by Tuxhorn et al who demonstrated expression in 7/7 samples of localized prostate cancer taken from core biopsies. Our goal, therefore, is to perform more extensive analysis of FAP expression in normal prostate, BPH, and various stages of prostate cancer including premalignant proliferative inflammatory atrophy (PIA), prostatic intraepithelial neoplasia (PIN), in addition to, various stages and grades of PCa, including organ-confined, androgen-dependent adenocarcinomas and hormone-refractory metastatic bone lesions. Studies to date on human tissue have relied on the commercially available F19 mouse anti-human FAP hybdridoma which we have available in our laboratory. A second mouse anti-FAP antibody has been purchased from Bender MedSystems. Both antibodies only recognize native FAP and only work on frozen tissue and in FACS analysis. The goal of these studies will be to determine the prognostic significance of FAP expression in human prostate cancer and to begin to gain an understanding of whether FAP may play a role in the pathobiology of the disease.

Recently a new anti-human FAP antibody from Vitatex that has the ability to recognize both dimeric and monomeric forms of native FAP, as well as, work in paraffin-embedded tissues has become commercially available. This antibody has been obtained from Vitatex and is currently being validated in paraffin-embedded samples. Once validation of this antibody has been completed we can begin our characterization of FAP expression patterns in both the normal prostate and in various disease states. The availability of an antibody that can be utilized in paraffin-embedded tissues, as opposed to frozen sections only, will allow us to perform more extensive analyses of FAP expression in archived prostate tissues and microarrays using greater numbers of samples to increase the statistical significance of any differences detected in the data.

Specific Aim 2: Identify a FAP-specific cleavable peptide sequence for the development of targeted prodrugs delivering a toxin (i.e., thapsigargin).

Peptide sequences specifically cleaved by FAP's enzymatic activity will be identified through the coordinated application of two different techniques. The first approach will be to perform traditional mapping of FAP cleavage sites within collagen I, a known FAP protein substrate. Dr. Denmeade's lab recently completed this digestive approach using recombinant collagen I derived gelatin produced in E coli so that no post-translational modifications occurred (i.e. proline hydroxylation). FAP cleavage sites within this gelatin were determined using LC-MS analysis performed in collaboration with Dr. Robert Cotter's group at Johns Hopkins who specialize in mass spectrometric-based proteomic techniques. This study yielded a large number of cleavage sites within the gelatin, but given that collagen is a heterotrimeric polymer made up of repeating sequences containing the (GXY)n motif (X= Pro, Y= HydroxyPro), the cleavage sites were of a limited repertoire. To obtain more complete analysis of FAP substrate requirements we will synthesize a positional scanning synthetic combinatorial library (PSSCL) employing a 4-amino-7-carbamoylmethylcoumarin (ACC) based resin that will enable the P1-P6 subsite specificity of the putative FAP substrates to be probed in a high throughput manner. The combined integration of consensus sequences detected through each of these screens should allow the identification of highly-specific FAP cleavable peptide sequences that can be linked to a highly cytotoxic compound such as thapsigargin to generate a prodrug that is selectively activated by FAP-positive reactive stromal cells within prostate cancer sites while avoiding toxicity to normal FAP-negative host tissues.

The cleavage products generated from the Collagen I derived gelatin digestion were ranked according to their normalized ion current. This value was calculated by extracting the ion current for the parent mass of the ion from the total MS ion chromatogram and then integrating under the peak from the liquid chromatogram. This ranking was performed in an attempt to quantify the relative abundance of each fragment within the mixture and consequently a preferred cleavage motif (Figure 4 of appended publication). The frequency of individual amino acids within the P7-P1' positions of each cleavage site were also determined to reveal a consensus peptide containing optimal residues in each position The basic pattern that emerged from this analysis was (D/E)-(R/K)-G-(E/D)-(A/G/S/T)-G-P-A or (acidic aa)-(G-(acidic aa)-(Small/Polar-OH aa)-G-P-A (Figure 5 of appended publication).

As a result of these analyses we selected several peptides representing high, intermediate, and low extracted ion currents from the gelatin digestion products, as well as, variations of the consensus peptide for further study. Fluorescence-quenched substrates based on the selected sequences were synthesized in order to ascertain Michaelis-Menten kinetic parameters (i.e. K_m , V_{max} , k_{cat}) of FAP hydrolysis. Substrates were ranked according to their calculated k_{cat}/K_m ratios (Table 2 & 3 of appended publication). In general, those substrates with the highest extracted ion currents were cleaved the most efficiently by FAP indicating that this normalization method is of benefit in identifying preferred cleavage motifs from digestion products. The critical importance of an amino acid in the P1' position was demonstrated based on the near abrogation of hydrolysis in substrates lacking a residue in this position. There was minimal improvement observed in substrates with additional amino acids on the P' side beyond the P1' position. See appended publication, 'Fibroblast Activation Protein (FAP) Peptide Substrates Identified from Human Collagen I-derived Gelatin Cleavage Sites' (Brennen, 2007) for additional information regarding methods and a more detailed discussion of the results found related to this aim. Synthesis of several fluorescence-quenched substrates containing hydroxyproline in the Y positon of the collagen (GXY)n motif has been performed in order to determine the potential role of this posttranslational modification in relation to FAP's efficiency of hydrolysis.

There has been a complication that has arisen in the synthesis of the 4-amino-7carbamoylmethylcoumarin (ACC) fluorophore for use in the positional scanning synthetic combinatorial library (PSSCL). The compound itself has been successfully synthesized as determined by nuclear magnetic resonance (NMR), however, addition of the Fmoc-protecting group to the primary amine has proven difficult. This protecting group is necessary for the directed coupling of the carboxylic acid moiety to the resin for solid-phase synthesis. Dave Meyers, director of the Pharmacology Synthesis Core on campus has been contacted for aid in the completion of this final step in the synthesis.

Specific Aim 3: Synthesize prodrug and measure kinetics in vitro using both human prostate cancer cell lines and cell-free assays.

Our goal for the second year of funding will be to evaluate selective FAP peptide substrates identified in Aim 2 linked via a peptide bond to amino acid containing 12ADT analogs. Synthesis of the prodrugs will not be initiated until further refinement of a selective cleavage motif has been completed based upon analysis of the PSSCL as outlined in Specific Aim 2. A lentiviral (LV) vector (EF.insert.PGK.GFP) has been obtained from Dr. Linzhao Cheng here at Johns Hopkins for use in the generation of cell lines stably transfected with the FAP construct. The full-length FAP coding sequence has been ligated into the LV vector, and I am currently selecting and sequencing clones of the 293T packaging cells. The LV vector offers the advantages of greater efficiency of integration into the genome, as well as, ease of stable transfectant selection through the use of FACS sorting based on GFP expression as compared to the pIRESneo3 vector as described in the original proposal.

Specific Aim 4: Determine the potential therapeutic benefit and toxicity of this prodrug in vivo using human prostate cancer xenografts in immunocompromised murine hosts.

On the basis of studies in Specific Aim 3, further in vivo studies will be performed on prodrugs ("leads") that possess the best combination of FAP hydrolysis, stability in plasma, selective toxicity to FAP-positive prostate cancer cells and minimal non-specific toxicity (i.e. goal of 20-60 fold differential). These in vivo studies will not be started until the successful completion of specific aims 1-3.

Key Research Accomplishments

Digestion and analysis of human Collagen I-derived gelatin using a tandem LC-MS/MS approach

Ranking of digestion products according to extracted ion Identification of preferred cleavage motifs within the human Collagen I-derived gelatin digestion products Identification of a consensus peptide containing optimal residues in each position, P7-

P1'. The basic pattern that emerged from this analysis was (D/E)-(R/K)-G-(E/D)-

(A/G/S/T)-G-P-A or (acidic aa)-(basic aa)-G-(acidic aa)-(Small/Polar-OH aa)-G-P-A. Synthesis of several fluorescence-quenched peptide substrates based on sequences

identified and selected from the digestion products

Determination of the Michaelis-Menten kinetic parameters (i.e. K_m , V_{max} , k_{cat}) for FAP hydrolysis of each of these substrates and ranking according to their k_{cat}/K_m ratios. Validation of normalization & ranking according to the extracted ion current

demonstrating a novel method for identifying preferred cleavage sites

Requirement for residue occupying P1' position of FAP substrate and minimal improvement with addition of >1aa on the P' side.

Reportable Outcomes

 Aggarwal S, Brennen WN, Kole TP, Schneider E, Topaloglu O, Yates M, Cotter RJ, Denmeade SR. <u>Fibroblast Activation Protein (FAP) Peptide Substrates Identified from</u> <u>Human Collagen I-derived Gelatin Cleavage Sites</u>. *Biochemistry*, 2007, 10.1021/bi701921b [epub ahead of print]
 Brennen WN, Aggarwal S, Kole TP, Yates M, Rosen M, Denmeade SR. <u>Fibroblast</u> <u>Activation Protein (FAP: Targeting the Reactive Stroma as a Novel Prodrug Therapy</u>.

Oct 2007. 5th General Meeting of the International Proteolysis Society; University of Patras, Greece.

 Brennen WN, Aggarwal S, Kole, TP, Topaloglu O, Schneider E, Becker R, Denmeade SR. <u>Fibroblast Activation Protein (FAP: Targeting the Reactive Stroma as a Novel</u> <u>Prodrug Therapy</u>. May 2007. Fellow Research Day, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Baltimore, MD. – Honorable Mention

Conclusion

The goals of this proposal are (1) to characterize the expression of FAP, a serine protease that is selectively expressed by reactive tumor stromal fibroblasts, in human prostate cancers and (2) to identify selective substrates for the unique proteolytic activity of FAP that can be incorporated into peptide-TG prodrugs that are selectively activated only within FAP-producing prostate cancer sites. The proposal, therefore, has the potential to impact prostate cancer in two significant ways. First, the proposal may identify a role for FAP as a prognostic or, potentially, even diagnostic marker. Second, the proposal describes a strategy to generate a novel prostate cancer targeted prodrug therapy that could selectively kill prostate cancer cells while having minimal side effects to normal tissue. We have thus far identified consensus motifs from FAP digested human collagen I-derived gelatin and ranked them according to their Michaelis-Menten kinetic parameters based on the hydrolysis of their respective fluorescence-quenched peptide substrates. Several promising candidate sequences have been identified and upon further refinement using a PSSCL approach will be used to generate potential FAP-selective prodrugs.

References

See Attached Appendix

Fibroblast Activation Protein Peptide Substrates Identified from Human Collagen I Derived Gelatin Cleavage Sites[†]

Saurabh Aggarwal,^{‡,§} W. Nathaniel Brennen,^{||} Thomas P. Kole,^{||} Elizabeth Schneider,[‡] Ozlem Topaloglu,[‡] Melinda Yates,^{||} Robert J. Cotter,^{||} and Samuel R. Denmeade^{*,‡,§,||}

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Chemical and Biomolecular Engineering Department, and Department of Pharmacology and Molecular Sciences, The Johns Hopkins University, Baltimore Maryland 21231

Received September 20, 2007; Revised Manuscript Received November 26, 2007

ABSTRACT: A highly consistent trait of tumor stromal fibroblasts is the induction of the membrane-bound serine protease fibroblast activation protein- α (FAP), which is overexpressed on the surface of reactive stromal fibroblasts present within the stroma of the majority of human epithelial tumors. In contrast, FAP is not expressed by tumor epithelial cells or by fibroblasts or other cell types in normal tissues. The proteolytic activity of FAP, therefore, represents a potential pan-tumor target that can be exploited for the release of potent cytotoxins from inactive prodrugs consisting of an FAP peptide substrate coupled to a cytotoxin. To identify FAP peptide substrates, we used liquid chromatography tandem mass spectroscopy based sequencing to generate a complete map of the FAP cleavage sites within human collagen I derived gelatin. Positional analysis of the frequency of each amino acid at each position within the cleavage sites revealed FAP consensus sequences PPGP and (D/E)-(R/K)-G-(E/D)-(T/S)-G-P. These studies further demonstrated that ranking cleavage sites based on the magnitude of the LC/MS/MS extracted ion current predicted FAP substrates that were cleaved with highest efficiency. Fluorescence-quenched peptides were synthesized on the basis of the cleavage sites with the highest ion current rankings, and kinetic parameters for FAP hydrolysis were determined. The substrate DRGETGP, which corresponded to the consensus sequence, had the lowest K_m of 21 μ M. Overall the K_m values were relatively similar for both high and low ranked substrates, whereas the k_{cat} values differed by up to 100-fold. On the basis of these results, the FAP consensus sequences are currently being evaluated as FAP-selective peptide carriers for incorporation into FAP-activated prodrugs.

The growth of epithelial neoplasms requires the formation of a supporting tumor stroma to supply nutrients and growth factors for tumor cell survival and continued growth. This invasive growth is associated with characteristic changes in the supporting stroma that include induction of tumor blood vessel formation, the recruitment of reactive stromal myofibroblasts, lymphocytes, and macrophages, the release of peptide signaling molecules and proteases, and the production of an altered extracellular matrix (1-5). The tumor stroma compartment represents a major component of the mass of most carcinomas, with 20-50% commonly seen in breast, lung, and colorectal cancers and reaching >90% in carcinomas that have desmoplastic reactions such as breast and pancreatic cancers (5, 6).

Unlike malignant epithelial cells, activated tumor stromal fibroblasts are not transformed genetically and do not demonstrate the genetic and phenotypic heterogeneity seen in malignant cells. Reactive tumor stromal fibroblasts differ from fibroblasts of normal adult tissues in regard to morphology, gene expression profiles, and production of important biological mediators such as growth factors and proteases (1, 6, 7). For example, a highly consistent trait of tumor stromal fibroblasts is the induction of fibroblast activation protein- α (FAP).¹ FAP was originally identified as an inducible antigen expressed on reactive stroma and given the name "fibroblast activation protein". FAP was independently identified by a second group as a gelatinase expressed by aggressive melanoma cell lines and was given the name "seprase" for surface-expressed protease (8). Subsequent cloning of FAP and seprase revealed that they are the same cell-surface serine protease.

FAP was originally reported to be a cell-surface antigen recognized on human astrocytes and sarcoma cell lines in vitro by the F19 monoclonal antibody (MAb) (9). In one series using human tissues, FAP was detected in the stroma of over 90% of malignant breast, colorectal, skin, and

[†] This work supported by funding from the Susan G. Komen Breast Cancer Foundation (to S.R.D.), the Department of Defense Breast Cancer Research Program (Grant DAMD17-03-1-0304) (to S.R.D.), and a Department of Defense Prostate Cancer Research Program Pre-Doctoral Award (to W.N.B.). The Mass Spectrometry/Proteomics Facility at the Johns Hopkins University School of Medicine is supported by NCRR Grant 1S10-RR14702, the Johns Hopkins Fund for Medical Discovery, and the Institute for Cell.

^{*} To whom correspondence should be addressed. Phone: (410) 502-3941. Fax: (410) 614-8397. E-mail:denmesa@jhmi.edu.

[‡] The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

[§] Chemical and Biomolecular Engineering Department.

Department of Pharmacology and Molecular Sciences.

¹ Abbreviations: FAP, fibroblast activation protein; LC/MS/MS, liquid chromatography/tandem mass spectrometry; MALDI-TOF, matrix-assisted laser desorption/ionization time of flight; Mca, 7-methoxy-coumarin-4-acetic acid; Dnp, dinitrophenyl.

pancreatic tumors (7, 10). In contrast, most normal adult tissues have demonstrated no detectable FAP protein expression (7). FAP expression has been most characterized in breast tissue. Garin-Chesa et al. used the F19 MAb to demonstrate strong (12/14) and moderate (2/14) expression of FAP in the stroma of human breast carcinomas but observed no expression by breast cancer epithelial cells and no expression in adjacent normal breast tissue. Additionally, little to no expression was observed in the stroma or epithelial cells of 10/10 samples of fibrocystic disease and 2/2 samples of fibroadenomas (7).

FAP is a member of the enzyme class known as postprolyl peptidases that are uniquely capable of cleaving the Pro-X amino acid bond. These enzymes have been demonstrated to play a role in cancer biology and are capable of modifying bioactive peptides (11). This group of proteases includes the well-characterized dipeptidyl peptidase IV (DPPIV) as well as DPPII, DPP6, DPP7, DPP8, DPP9, prolyl carboxypeptidase, and prolyl endopeptidase (11). The substrate preferences for many of these prolyl peptidases are not entirely known, but like DPPIV, they all have dipeptidase functionality. FAP is highly homologous to DPPIV (11). Like DPPIV, FAP is a type II integral membrane protein that is able to cleave peptides with proline as the penultimate amino acid (12). However, FAP differs from DPPIV in that it also has gelatinase and, possibly, collagenase activity (8, 11). Using zymography, FAP was demonstrated to cleave gelatin and human collagen I but was unable to cleave human fibronectin, laminin, or collagen IV (12). These results suggest that FAP's physiologic function may be primarily that of an endopeptidase that can degrade proteins rather than a dipeptidase like DPPIV. This additional gelatinase/collagenase activity may be unique to FAP among the family of prolyl proteases. Unlike DPPIV, FAP is also not widely expressed in most normal tissues (11).

Our laboratory has been engaged in the development of prodrugs that can be selectively activated by tissue-specific proteases (13-17). These prodrugs are produced by coupling a cytotoxic agent to a peptide carrier to produce an inactive compound that can only become activated upon release of the cytotoxin from the peptide by proteolysis. Our initial efforts have focused on the development of prodrugs activated by the prostate cancer serine proteases prostatespecific antigen (PSA) and human glandular kallikrein 2 (hK2) that are both members of the kallikrein family (13-16). In contrast to this tissue-specific approach, FAP represents a potential pan-tumor target. To develop FAPactivated prodrugs requires the identification of a peptide substrate that is selectively hydrolyzed by FAP. In the current study, we present results using liquid chromatography/tandem mass spectrometry (LC/MS/MS) to generate a complete map of FAP cleavage sites within recombinant forms of human collagen I derived gelatin. We have synthesized selected peptides on the basis of these cleavage maps and analyzed them for hydrolysis by FAP to identify peptides that could be used to target cytotoxins to FAP-expressing tumor tissue.

EXPERIMENTAL PROCEDURES

Materials. The *Drosophila* Expression System (DES) was from Invitrogen (Rockville, MD). Peptide Ala-Pro-AFC [AFC = 7-amino-4-(trifluoromethyl)coumarin] was from Bachem (Heidelberg, Germany). Gly-Pro-AMC, the MMP substrate sampler kit, and all other peptide synthesis reagents were from Anaspec (San Jose, CA). Novatag Dnp resin, *N*-(7-methoxycoumarin-4-acetyloxy)succinimide (Mca-Osu), 1-hydroxybenzotriazole (HOBt), and *N*-methyl-2-pyrrolidone (NMP) were from Novabiochem, San Diego, CA. Unless otherwise indicated all the other reagents were from Sigma-Aldrich (St. Louis, MO).

FAP Cloning and Expression. A PCR approach was used to amplify and attach a His₆ tag to the amino terminus of the extracellular domain of FAP (Genbank accession number NM_004460). The primers used were (forward Bg/II) 5'-GGAAGATCTCATCATCACCATCACCATCGCCCT-TCAAG-3' and (reverse XhoI) 5'-GGCCTCGAGTCATT-AGTCTGACAAAGAGAAAACACTGC-3'. Template amplification was performed using Pfu polymerase (Promega, Madison) as per the suggested protocol. A PCR reaction began with an initial denaturation step (94 °C for 2 min) followed by three cycles of amplification (94 °C for 30 s, 40 °C for 1 min, 72 °C for 2 min), followed by 30 cycles of amplification (94 °C for 30 s, 58 °C for 1 min, 72 °C for 2 min), and ended with a final extension step (72 °C for 10 min). A 2 kb PCR fragment was purified by gel electrophoresis, digested with Bg/III/XhoI, and cloned into pMT/ BiP/V5-HisA (Invitrogen, California) previously digested with the same set of enzymes. The final construct was designated as pMT-His-FAP.

Transfection of Insect Cells and Stable Cell Line Generation. Schneider's S2 cells (Invitrogen) were maintained in DES medium (Gibco, Rockville, MD) supplemented with 10% heat-inactivated fetal bovine serum (FBS) at room temperature. Before transfection, the cells were seeded in a 35 mm dish and grown until they reached a density of (2-4) \times 10⁶ cells/mL. The cells were cotransfected with 19 μ g of pMT-His-FAP and 1 μ g of a pCoHYGRO selection vector using a kit for calcium phosphate-mediated transfection (Invitrogen). The calcium phosphate solution was removed 16 h post-transfection, and fresh DES medium supplemented with 10% FBS was added (a complete medium). The cells were grown for an additional 2 days, and then the medium was replaced with the complete medium containing 400 µg/mL hygromycin B (Invitrogen). The selection medium was changed every 3-4 days. Extensive cell death of nontransfected cells was evident after about 1 week, and cells resistant to hygromycin B started to grow out 2-3 weeks post-transfection.

His-Tagged FAP Large-Scale Expression and Purification. The hygromycin-resistant cells were seeded in 10 T-150's at a density of 1 million cells/mL. When the cells reached a density of 2–3 million cells/mL, 500 μ M CuSO₄ was added to induce FAP expression. The cells were grown until they reached a density of 10-15 million cells/mL (8-9 days). A 2 mL portion of 200 mm L-glutamine was added to the cell suspension on days 2 and 6. Conditioned medium containing secreted FAP was collected after 12-14 days. The medium was concentrated, and excess CuSO₄ was removed by three rounds of ultrafiltration using an Amicon 8480 membrane (Millipore) with a 30 000 kDa cutoff. After each round of ultrafiltration, the volume was made up using sterile water. Final purification was obtained by incubating the concentrate with Ni-NTA resin (Qiagen, California) in manufacturerrecommended salt and imidazole concentrations. FAP was eluted from the resin using 250 mM imidazole. The final 30 mL of eluate was diluted with water to 300 mL, and imidazole was removed by two rounds of ultrafiltration. The purity was checked by SDS–PAGE and Coomassie staining. Western blots were probed with anti-His tag [penta-His–horse radish peroxidase (HRP) conjugate from Qiagen). Overall, a yield of 1–2 mg was obtained from a 700 mL culture. Final purified aliquots were stored in reaction buffer at -20 °C.

FAP Enzyme Activity. FAP dipeptidyl peptidase activity was determined by digesting 500 µM Ala-Pro-AFC (Calbiochem) with rhFAP as described by Park et al. (12). Assays were performed at 23 °C in 100 mM Tris, 100 mM NaCl at pH 7.8 in 10% DMSO and 0.3% Brij-35. The fluorescence output was monitored every 30 s using a DTX 880 multimode detector (Beckman Dickinson). Standard curves of AFC (Calbiochem) fluorescence vs concentration were run with each assay to convert relative fluorescence units to moles of product generated. Excitation/emission wavelengths of 370 and 535 nm, respectively, were used to monitor liberation of the AFC fluorophore. The rate of hydrolysis (mol/min) was ascertained by determining the slope during the first minute of the reaction. This rate was then used to calculate the enzyme units per unit volume with 1 unit of enzyme activity being defined as the cleavage of 60 μ mol of substrate/min.

FAP Gelatinase Assay. Quenched gelatin and collagen conjugates were used to detect and confirm FAP's gelatinase and collagenase activity. DQ gelatin from pig skin and DQ collagen type IV from human placenta fluorescencequenched conjugates (Invitrogen, Rockville, MD) were digested with FAP, and digestion was monitored on a fluorescence plate reader. Protein substrates were dissolved in reaction buffer (100 mM NaCl, 100 mM Tris, pH 7.8) to a final concentration of 100 μ g/mL. Trypsin digestion of each protein was used as a positive control. As a negative control the His-tagged extracellular domain of prostate-specific membrane antigen (PSMA), which was similarly purified from S2 cells under the same conditions as FAP, was also incubated with the quenched proteins. Fluorescence-quenched DQ bovine serum albumin (BSA) was used as a negative control for FAP protease activity.

Digestion of Recombinant Gelatin with FAP for Cleavage Mapping. Recombinant human gelatins of 100 and 8.5 kDa (Fibrogen, San Francisco, CA) were dissolved in reaction buffer, and 1 μ g of FAP was added per 100 μ g of protein substrate. Digestion was done for 4-6 h at 37 °C. As a positive control, trypsin digestion was performed. As a negative control, protein solutions were incubated with either BSA/buffer or buffer alone. Peptide fragments of size <30 kDa were purified using a 30 kDa Microcon spin filter (Millipore, Billerica, MA). The fragments were further purified with C₁₈ spin tubes (Agilent, Palo Alto, CA) as per the suggested protocol with the substitution of 0.5% acetonitrile in place of 5% for binding and washing of the C₁₈ columns. Samples were prepared for matrix-assisted laser desorption/ionization time of flight (MALDI-TOF) analysis on an Applied Biosystems Voyager-DE STR (mass accuracy \geq 100 ppm) by 100:1 dilution with 2.5-dihydroxybenzoic acid (DHB) as the matrix. Analysis was performed in the linear mode over a mass acquisition range of 500-5000 Da with 50 laser shots performed per spectrum. Instrument calibration

was performed routinely by the Mass Spectrometry Core Facility and was not performed prior to individual analyses.

Nanoflow HPLC and Mass Spectrometry. Peptides obtained from the FAP/gelatin digests were dried using a SpeedVac (Eppendorf), resuspended in LC/MS loading buffer (3% ACN, 0.1% formic acid), and analyzed using nanoflow LC/MS/MS on an Agilent 1100 series nano-LC system (Agilent) coupled to an LCQ DUO ion trap mass spectrometer (ThermoFinnigan). The LCQ was calibrated (m/z 50-2000) using the automatic calibration procedure outlined by the manufacturer. A fused silica capillary was loaded with a solution containing the Met-Arg-Phe-Ala (MRFA) peptide, caffeine, and Ultramark 1621 in 50% acetonitrile/0.1% formic acid. The capillary was connected to the nanoflow HPLC instrument and sprayed into the LCQ using the same flow rate and spray voltage used in all subsequent experiments. The calibration was tested using a standard 100 fmol tryptic digest of BSA and demonstrated a mass accuracy of ≤ 0.5 Da.

Peptides were preconcentrated on a 5 mm Zorbax C18 trap column (Agilent) and then eluted onto a 100×0.075 mm custom-packed Biobasic C18 (ThermoElectron) reversedphase capillary column connected to a laser-pulled electrospray ionization emitter tip (New Objective) at a flow rate of 300 nL/min. Peptides were eluted from the nanospray source of the LCQ (Proxeon, Denmark) using the following gradient: 0% B at 0 min, 5% B at 8 min, 45% B at 50 min, 90% B at 55 min, 90% B at 60 min (solvent B is 0.1% formic acid in acetonitrile) at a spray voltage of 2.5 kV. The LCQ was operated in data-dependent mode using the Xcalibur software (ThermoFinnigan) in which every MS scan (400-1800 m/z) was followed by MS/MS scans (400-1800 m/z) on the three most intense ions using an isolation window of ± 1.5 Da. Ions selected for MS/MS fragmentation were dynamically excluded for 30 s.

MS/MS data were searched against a collagen FASTA database using the SEQUEST search algorithm built into the Bioworks Browser (ThermoFinnigan), allowing for the variable modification of methionine oxidation. The peptides were initially filtered in a charge-dependent manner using an XCorr filter of 1.5, 2, and 2.5 for singly, doubly, and triply charged peptides. All MS/MS spectra used to identify peptides were manually inspected for validation of the y and b ion series. To quantify the relative abundance of each identified peptide, we compared the ion current for each of the observed peptide parent ions from the MS spectra. The contribution of each parent ion to the total ion current was extracted and integrated over the peptide elution peak.

Synthesis of Substrates Based on Determined Cleavage Sites. Quenched peptide substrates were prepared by using the 7-methoxycoumarin-4-acetic acid (Mca)/Dnp fluorophore/quencher pair. Synthesis of peptides was done using standard Fmoc solid-phase coupling on NovaTag Dnp resin with a substitution level of 0.4 mmol/g (Novabiochem, San Diego, CA). N-terminal capping was done twice overnight with Mca-Osu and HOBt in NMP. The peptides were cleaved with 95% TFA, 2.5% TIS, and 2.5% water. The purity and mass of each quenched peptide was confirmed by reversedphase HPLC and MALDI-TOF analysis.

Protease Assays. The substrates were dissolved in DMSO at a stock concentration of 10 mM. Working concentrations of each substrate were made by making 2-fold dilutions



FIGURE 1: Characterization of recombinant His-tagged FAP. (A) Hydrolysis of the dipeptide substrate Ala-Pro-AFC (500 μ M) by FAP (5 μ g/mL) compared to DPPIV. The inset shows Western blot analysis of purified His–FAP following denaturing SDS–PAGE. (B) Digestion of indicated FITC-labeled proteins (100 μ g/mL) by FAP (5 μ g/mL).

ranging from 500 to 7.9 μ M. rhFAP (10E-4 units, ~210-230 nM depending on the specific activity of the enzyme) was added to each assay where enzyme was included. The fluorescence of the cleavage product resulting from protease activity was monitored every 30 s using a DTX 880 multimode detector (Beckman Dickinson). Standard curves of Mca (Novabiochem) fluorescence vs concentration were run with each assay to convert relative fluorescence units to moles of product generated. Excitation and emission wavelengths of 340 and 435 nm, respectively, were used to monitor liberation of the Mca fluorophore peptide cleavage fragment. Assays were performed at 23 °C in 100 mM Tris, 100 mM NaCl at pH 7.8 in 10% DMSO and 0.3% Brij-35. Kinetic constants (K_m and k_{cat}) were calculated on the basis of the rate of hydrolysis (v) during the first minute of the reaction. Kinetic parameters were calculated from Michaelis-Menten plots (v vs [S]) with nonlinear regression analysis using SigmaPlot software.

RESULTS

Purification of Enzymatically Active FAP. The characterization of protease substrate specificity requires that the protease be of maximum purity and correctly folded to maintain enzymatic activity. Previously it had been shown that full-length FAP, cloned and expressed in Drosophila S2 cells, yielded highly pure protein that was enzymatically similar to the human form (18). Therefore, the extracellular domain of FAP was cloned with a His₆ tag at its N-terminus to generate a stable FAP-producing Drosophila S2 cell line. On induction with CuSO₄, FAP was secreted into the medium, which was then concentrated by ultrafiltration and purified using Ni-NTA beads. Purified FAP was demonstrated to be enzymatically active via its ability to cleave the dipeptide substrate Ala-Pro-AFC (18) (Figure 1A). Western blot analysis with an anti-His tag MAb documented the correct protein size of \sim 80 kDa (Figure 1A, inset).

Recombinant FAP Retains Gelatinase Activity. Quenched forms of gelatin and collagen were used to confirm the gelatinase and collagenase activity of recombinant FAP. Quenching is achieved by heavily labeling these proteins with the fluorophore FITC such that the fluorescence signal from the intact protein is minimal due to self-quenching by the fluorophore. Protein digestion releases FITC-labeled fragments that result in a measurable increase in overall

fluorescence signal from the reaction mixture. Previously, it had been demonstrated using gel zymography that FAP can cleave gelatin and collagen I but could not cleave collagen IV (12). It remains unclear whether FAP can digest collagen I directly as recent studies suggest that the observed digestion may be due to an artifactual conversion of collagen I to gelatin during preparation (12, 19, 20). To confirm that our recombinant FAP maintained the ability to cleave gelatin, we used the FITC-quenched protein DQ gelatin from pig skin, with DQ collagen IV from human placenta serving as a negative control. In this assay, gelatin was readily hydrolyzed by FAP while collagen IV was not hydrolyzed (Figure 1B). MALDI-TOF analysis of the digested fragments was performed to confirm FAP hydrolysis. As a negative control, we demonstrated no digestion of any of the proteins using His-tagged human carboxypeptidase PSMA purified from Drosophila S2 cells under the same conditions (data not shown). These results confirm that gelatin hydrolysis was due to FAP and not due to the presence of some other protease contaminating our purification system.

MALDI for FAP Digest of Denatured Human Collagen I. To elucidate the substrate specificity of FAP, we examined FAP digests of unlabeled denatured human collagen I using MALDI-TOF mass spectrometry (Figure 2A). Digestion reactions were performed at a substrate to protease mass ratio of 200:1 using recombinant FAP or modified trypsin as a control. Two negative controls of collagen alone and FAP alone were also included to identify any peptides due to autolysis/degradation of these proteins. SDS-PAGE analysis of FAP-digested denatured collagen I (not shown) produced a smear of continuous size fragments, suggesting the presence of many cleavage sites. To simplify cleavage mapping by MALDI-TOF, small fragments (<5 kDa) were isolated by ultrafiltration and further purified using reversed-phase chromatography, Figure 2A. MALDI-TOF was subsequently performed using serial dilutions of the isolated peptides.

The masses of singly charged ions $[M + H]^+$ obtained from MALDI spectra were entered into the FindPept search tool at the ExPASy proteomics server (http://www.expasy-.org/tools/findpept.html) and used to perform a peptide mass fingerprint (PMF) search against the known collagen sequence. MALDI spectra suggest that denatured human collagen I is cleaved by FAP at numerous specific sites (Figure 2A); however, we were unable to unambiguously



FIGURE 2: (A) MALDI-TOF mass spectra demonstrating FAP digestion of human collagen I. (B) Example of cleavage site sequence(s) determination using the FindPept tool for a selected mass of 2114.5 from MALDI-TOF mass spectra. Multiple potential cleavage site sequences within ± 1 mass unit are identified by this analysis.

identify the cleavage sequences using the FindPept tool (Figure 2B). In most cases, multiple peptide sequences were matched for the same mass, and in some instances, more than 30 sequences were obtained for one particular mass. This result was most likely due to the fact that human collagen I is a heterotrimeric polymer made up of repeating sequences containing the $(GXY)_n$ motif (where X = Pro and Y = hydroxy-Pro). Human collagen I is also known to be glycosylated and cross-linked randomly throughout its sequence (21). These post-translational modifications in human collagen have not been well characterized and, therefore, make it more difficult to determine the exact cleavage sites using MALDI-TOF coupled with other proteomics tools. These results, while demonstrating that FAP cleaved denatured human collagen I, demonstrated the difficulties in obtaining correct cleavage sequences by mass spectrometry due to the polymeric nature and poorly defined qualities of human collagen I.

LC and Tandem MS/MS Analysis of FAP Digestion of Recombinant Gelatin. As collagen I derived gelatin is currently one of the only known protein substrates for FAP, we needed to develop an alternative method to identify FAPselective cleavage sites within these proteins. To solve the problem of post-translational modification, we identified a source of recombinant human gelatin and collagen from FibroGen (South San Francisco, CA) that was prepared by cloning the human collagen I sequence in a strain of *Pichia pastoris* which lacks the enzyme prolyl hydroxylase (22). This human collagen I based gelatin is well characterized and has no post-translational modifications. This gelatin is used to produce drug capsules and vaccine adjuvants. Therefore, this recombinant gelatin was used in subsequent FAP cleavage mapping studies.

We next used MALDI-TOF to analyze FAP digestion of the 100 kDa recombinant form of human gelatin. SDS-

	Cleavage Fragment		Theoretical [M+H]+	Charge	m/z (observed)
PPGAVGP/	AGKAQGPPGP/	AGP	1308.62	2	654.81
-	GLP SPGSPGP/	DGK	1449.77	2	725.39
KTGPPGP/	AGQPPGPPGA/	RGQ	1330.65	2	665.83
VMGFPGP/	KGAPPGAVGP/	AGK	2113.12	2	1057.06
VMGFPGP/	KGAGEPGKAG/	ERG	942.5	1	942.50
-	GLPKTGPPGP/	AGQ	2256.16	2	1128.58
GFPGPKG/	AAGPPGAVGP/	AGK	1928	2	964.50
FPGPKGA/	AGE PPGAVGP/	AGK	1856.96	2	928.98
LTGSPGS/	PGPKTGPPGP/	AGQ	1076.54	2	538.77
KTGPPGP/	AGQGPPGPPG/	ARG	1259.61	1	1259.61
VMGFPGP/	KGAAGEPGKA/	GER	885.48	1	885.48
GLPGAKG/	LTGSPGSPGP/	DGK	869.44	1	869.44
MGFPGPK/	GA- AGEPGKA/	GER	757.38	1	757.38
PGPPGAR/	GQAVMGFPGP/	KGA	1017.48	1	1017.48
PGARGQA/	G- VMGFPGP/	KGA	761.37	1	761.37
GPPGPPG/	ARGVMGFPGP/	KGA	1244.62	2	622.81
PPGPPGA/	RGQVMGFPGP/	KGA	1173.58	2	587.29
KTGPPGP/	AGQ GARGQAG/	VMG	1799.89	2	900.45

В.

Α

481 glpgakg 541 tgspgspgpd gktgppgpag qdgrpgppgp pgargqagvm gfpgpkgaag epgkagergv

601 pgppgavgpa gkdgeagaqg ppgpagpage r

FIGURE 3: (A) FAP cleavage sites within the 8.5 kDa fragment of recombinant human collagen I derived gelatin. Cleavage sites are bracketed by "/", and $[M + H]^+$ denotes the mass of the cleavage fragment. Amino acids on the N-terminal side of the cleavage site (i.e., P7–P1) are in bold font. (B) Amino acid sequence of the 8.5 kDa fragment with FAP cleavage sites indicated by arrows.

PAGE separation and MALDI-TOF spectra showed that FAP readily digests the recombinant gelatin (data not shown). The masses of fragments <3 kDa were purified for MALDI-TOF spectra and again analyzed using the FindPept tool. However, once again multiple peptide sequences were obtained for each cleavage fragment.

Therefore, to resolve each particular mass fragment, an LC/MS/MS method was developed. To initially work out the methodological issues, peptide fragments from the FAP digest of the 8.5 kDa recombinant gelatin were time-resolved by nano-reversed-phase LC and then sequenced using an ion trap mass spectrometer operating in MS/MS mode (Figure 3A). MS/MS spectra were searched against the 8.5 kDa gelatin sequences using the SEQUEST algorithm with no cleavage specificity. In this analysis most of the identified cleavage sites occurred after proline. However, FAP cleavage sites in these gelatins were not restricted to proline alone. FAP was also found to cleave after Ala, Arg, Gly, Lys, and Ser. FAP was also able to cleave after multiple adjacent amino acids within the 8.5 kDa gelatin fragment (Figure 3B).

FAP Cleavage Map for Full-Length 100 kDa Gelatin. On the basis of the results with the 8.5 kDa gelatin fragment, we proceeded to use this LC/MS method to identify all of the FAP cleavage sites within the full-length 100 kDa recombinant gelatin. In an effort to identify the most preferentially cleaved sites, we also quantified the relative abundance of each of the identified peptides by integrating the ion current generated by each peptide throughout the chromatogram (Figure 4). After identification of a peptide from an MS/MS spectrum, we extracted the ion current for the parent mass of the ion from the total MS ion chromatogram using a 1.5 Da tolerance window and then integrated under the peak. In the case of multiple peaks, we chose the peak nearest to the retention time of the MS/MS spectrum matched to the peptide sequence of interest.

This analysis revealed a total of 51 FAP cleavage fragments within the 100 kDa recombinant gelatin (Figure 4). The corresponding fragment was mapped within the recombinant gelatin to determine the sequence of the amino acids upstream of the FAP cleavage site toward the N-

	Theoretical		m/z	Extracted	
	Fragment	[M+H]+	Charge	(observed)	Ion Current
RTGDAGP/	VGP PGPPGP	1373 72	1	1373 72	1 48F+11
ASGPAGP/	RGP INGLPGP/ IGP	1871.97	2	936.49	4 94E+10
DRGETGP/	AGP APGAPGP/ VGP	1170 59	1	1170 59	2 34E+10
DRGETGP/	AGP DRGETGP/ AGP	2536.25	2	1268.63	2.15E+10
EPGPPGP/	AGEDAGPPGP/ AGP	2828.32	3	943.44	1.52E+10
RTGDAGP/	VGP PGPPGPP/ GPP	871 47	1	871.47	1.32E+10
GETGPAG/	PPG DRGETGP/ AGP	2408 20	3	803.40	1.45E+10
OPSGPAG/	PTGEPGPPGP/ AGE	1742.86	2	871.93	1.31E+10
PSGPAGP/	TGAEPG PPGP/ AGE	1645.81	2	823.40	1.21E+10
PAGAAGP/	AGNFPGARGP/ SGP	2812.39	2	1406.69	1.07E+10
PAGPPGA/	PGADRGETGP/ AGP	2086.03	2	1043.52	9.34E+09
FOGLPGP/	AGPDLGAPGP/ SGA	2112.04	2	1056.52	9.26E+09
MGFPGP/	KGAPPGAVGP/ AGK	2113.12	2	1057.06	7.40E+09
PPGPAGP/	AGPRVG PPGP/ SGN	3556.85	3	1186.28	6.68E+09
RVG PPGP /	SGN PPGPPGP/ AGK	1004 48	1	1004 48	5 99E+09
AGRVGPP/	GPS_AGPPGPP/ GPA	1004 48	1	1004 48	5.85E+09
PPGAPGP/	OGE EPGASGP/ MGP	1665.75	1	1665 75	5 76E+09
ETGPAGP/	PGA DRGETGP/ AGP	2311.14	2	1156.07	4.82E+09
PPGAPGA/	PGA DRGETGP/ AGP	1860.92	2	930.96	4 39E+09
GLTGPIG/	PPG DKGESGP/ SGP	1390.66	2	695.83	4 22E+09
DRGETGP/	AGP APGPVGP/ AGK	1423 73	1	1423 73	3.85E+09
ESGPSGP/	AGP_EPGPPGP/AGE	1870.92	2	935.96	3.34E+09
PRGETGP/	AGR_PPGPPGP/ AGE	1341.69	2	671.35	3.31E+09
VRGLTGP/	IGP DKGESGP/ SGP	1560.77	1	1560 77	2 79E+09
PPGPTGP/	AGPAKGEAGP/ OGP	1536.78	2	768.89	2.61E+09
FPGLPGP/	SGE ERG PPGP / MGP	1905 91	2	953.45	2.18E+09
PPG PPGP /	AGE APGTPGP/ OGI	1747.83	$\frac{1}{2}$	874 41	2.15E+09
LTGPIGP/	PGP DKGESGP/ SGP	1293.61	1	1293.61	2.115±+09
AKGDAGP/	AGPGENGAPG/ OMG	1478.69	1	1478.69	1.48E+09
VMGFPGP/	KGAAOGPPGP/ AGP	3402.72	3	1134.91	1.44E+09
PPGPAGA/	PG- DKGESGP/ SGP	843.39	1	843.39	1.14E+09
PPGPMGP/	PGLEGSPGRD/ GSP	2275.07	2	1138.04	1.06E+09
GFPGLPG/	PSGERGPPGP/ MGP	2002.96	2	1001.98	1.01E+09
PPGPTGP/	AGPEPGPPGP/ AGA	3530.75	3	1177.58	9.13E+08
APGAPGA/	PGPDRGETGP/ AGP	1635.81	2	818.40	8.35E+08
PRGSEGP/	OGVEPGPPGP/ AGA	1147.59	1	1147.59	8.14E+08
TGDAGPV/	GP- PGPPGPP/ GPP	772.40	1	772.40	7.43E+08
GPAGFAG/	PPG DAGPPGP/ AGP	2425.14	3	809.05	6.91E+08
AKGEPGP/	VG- VOGPPGP/ AGE	807.44	1	807.44	6.87E+08
AGPPGAD/	GOPDAGPPGP/ AGP	1987.95	2	994.47	5.43E+08
LPGPSGE/	PGKERGPPGP/ MGP	1632.81	2	816.90	3.83E+08
GLTGPIG/	PPGAGAPGDK/ GES	963.49	2	482.25	3.01E+08
KTGPPGP/	AGOGARGOAG/ VMG	1799.89	2	900.45	2.10E+08
GAKGDAG/	PPGPAG PPG P/ IGN	1068.55	1	1068.55	1.59E+08
RGETGPA/	GPPAPGAPGP/ VGP	1099.55	1	1099.55	1.31E+08
ATGFPGA/	AG- RVGPPGP/ SGN	807.45	1	807.45	1.03E+08
PGPAGQD/	GRPGARGQAG/ VMG	1428.75	2	714.87	7.53E+07
SGPRGLP/	G- PPGAPGP/ OGF	649.33	1	649.33	7.18E+07
PPGAVGP/	AGK AQGPPGP/ AGP	1308.62	2	654.81	5.98E+07
AGPPGPA/	G- PAGPPGP/ IGN	649.33	1	649.33	4.23E+07
PSGPQGP/	GGPAPGSKGD/ TGA	1819.86	2	910.43	3.58E+07

FIGURE 4: FAP cleavage sites within the 100 kDa recombinant human collagen I derived gelatin. Cleavage sites are bracketed by "/". The mass of the cleavage fragment, $[M + H]^+$, and extracted ion current are included for each cleavage site. Underlined sequences indicate cleavage sites which do not contain Pro (P) in the P1 position. The consensus sequences PPGP and D-(R/K)-G-E-(T/S)-G-P are indicated by bold text.

terminus. Since each fragment was produced by two cleavage events, 101 peptide sequences corresponding to the amino acids from P7 to P'1 could be mapped. Cleavage fragments were then ranked on the basis of the extracted ion current generated by each peptide (Figure 4). This ranking again revealed that FAP preferred to cleave after the G-P dipeptide. FAP was also able to cleave after other amino acids (i.e., Ala, Asp, Gly, Glu, Lys, and Val), but the majority of these cleavage fragments had very low extracted ion currents and were ranked in the lower half of the list (Figure 4). Often these non-proline cleavage sites were adjacent to a proline cleavage site. This result was also observed with the 8.5 kDa digest and suggested that the gelatin protein may misalign within the FAP catalytic site, resulting in low-level cleavage after non-proline amino acids. On the basis of these cleavage sites, the frequency of individual amino acids within the P7-P'1 positions of each cleavage site was next determined. This analysis was somewhat limited by the repetitive nature of the collagen I sequence, and it was, therefore, not necessarily unexpected that the most frequent amino acids at each position were either proline or glycine, producing a consensus peptide with the sequence PPGPPGP. This exact sequence is found in 3 of the sequences within the map, while the peptide PPGP is found in 21 of the 101 sequences.

The frequency analysis, however, did reveal some additional trends that could bear on the identification of consensus sequences to be used in the development of FAPactivated peptide prodrugs (Figure 5). After proline in P7, for instance, the acidic amino acids Asp (23%) and Glu



FIGURE 5: Frequency (%) of each amino acid in positions P7-P'1 within the FAP cleavage sites within the 100 kDa recombinant human collagen I derived gelatin. Gray bars indicate the frequency for all 101 cleavage sites. Black bars indicate the frequency in only those cleavage sites containing Pro (P) at the P1 position. The amino acids C, H, W, and Y are not present in human collagen I and, therefore, are not included.

		total no. of	no. of						
P7 P	P6	Р5	P4	P3	P2	P1	P1′	G-P cleavage sites ^a (%)	FAP-cleaved sites ^b (%)
					G	Р		116 (100)	40 (34)
					G	Р	А	28 (24)	20 (71)
D/E	K/R	G	D/E	A/G/S/T	G	Р		4(3)	3 (75)
A/D/E/P	K/R	G	D/E/P	A/G/S/T/P	G	Р		14 (12)	8 (57)
D/E	K/R/P	G	D/E/P	A/G/S/T/P	G	Р		8(7)	6 (75)
combined ^c								15 (13)	9 (60)
D/E/P	K/R/P	G	D/E/P	A/G/S/T/P	G	non-Pro		7 (6)	0(0)

Table 1: Frequency Analysis of Consensus Sequences within the 100 kDa Gelatin Amino Acid Sequence

^{*a*} Occurrence of the G-P dipeptide sequence in the 100 kDa gelatin sequence. ^{*b*} Number of times FAP cleaves after G-P sites. ^{*c*} Total unique sites from the consensus sequence indicated in rows 3–5.

(15%) were found in ~38% of the sequences. In P6, 30% of the sequences contained one of the basic amino acids Lys (10%) and Arg (20%). In P4, Glu was observed in 20% of the sequences and Asp in 4%. In P3, the small polar amino acids Ser and Thr, which both contain a -OH functional group, were found in 24% of the sequences and Ala and Gly with a small or no side chain were found in 26%. Finally, in the P'1 position, Ala was observed in almost half of the sequences (Figure 5). On the basis of this analysis, a second consensus sequence emerged [i.e., (D/E)-(R/K)-G-(E/D)-(A/G/T/S)-G-P-A or (acidic AA)-(basic AA)-G-(acidic AA)-(small/polar OH AA)-G-P-A)]. This consensus sequence is found in 15 of the 101 peptide sequences within the cleavage map (Figure 4).

To determine whether these consensus sequence motifs represented FAP-preferred cleavage sites or instead were merely observed due to a relative abundance of these particular sequences within the overall gelatin amino acid sequence, we evaluated the frequency of occurrence of these sites within the gelatin protein (Table 1). Overall there were 66 FAP cleavage sites within the 100 kDa recombinant gelatin. A total of 116 G-P sites are found within the protein, and 40 (34%) of these were cleaved by FAP, Table 1. To emphasize the importance of the Ala in the P'1 position, 28 sites with the tripeptide G-P-A exist in the gelatin sequence (24% of total G-P-containing sites). However, when present, 71% of these sites were cleaved by FAP. In addition, on the basis of the cleavage site analysis, we evaluated the frequency

Table 2: Enzyme Kinetics of FAP Substrates Generated from Cleavage Sites within 100 kDa Gelatin

no.	substrate sequence	$K_{\rm m}$ (μ M)		V _m (mol/s)	$k_{\rm cat} ({\rm s}^{-1})$	$k_{\rm cat}/K_{\rm m} ({ m M}^{-1}{ m s}^{-1})$	normalized ion current rank	
1	Mca-ASGPAGPA-Dnp	36.1 ± 2.7	2.26E-	$-12 \pm 8.14 \text{E}{-14}$	0.196 ± 0.007	5441 ± 478	2	
2	Mca-EPGPPGPA-Dnp	26.9 ± 0.7	1.32E-	$-12 \pm 9.53E - 14$	0.115 ± 0.006	4270 ± 90	5	
3	Mca-DRGETGPA-Dnp	21.0 ± 2.2	8.50E-	$-13 \pm 1.89 \text{E}{-14}$	0.081 ± 0.002	3851 ± 366	3, 4, 7	
4	Mca-VGPAGK-Dnp	52.0 ± 4.4	1.09E-	$-12 \pm 4.41 \text{E}{-14}$	0.095 ± 0.004	1822 ± 100	13, 21	
5	Mca-DKGESGPA-Dnp	46.0 ± 3.5	7.69E-	$-13 \pm 2.11E - 14$	0.067 ± 0.001	1453 ± 99	20, 24	
6	Mca-APGSKGDA-Dnp	51.0 ± 11.8	1.68E-	$-13 \pm 1.95 \text{E}{-13}$	0.015 ± 0.017	286 ± 391	51	
Table 3: Enzyme Kinetics of FAP Substrates Derived from the Consensus Sequence DRGETGPA								
no.	substrate sequence	Kr	η (μM)	$V_{\rm m}$ (mol/s)	$k_{\rm cat} ({\rm s}^{-1})$	$k_{\rm cat}/K_{\rm m} ({ m M}^{-1}{ m s}^{-1})$	
7	Mca-DRGETGP-Dnp	23.8	3 ± 6.8	3.49E-14	$\pm 8.02E - 15$	0.003 ± 0.001	127 ± 31.9	
8	Mca-DRGETGPA-Dnp	21.0	$) \pm 2.2$	8.50E-13	$\pm 1.89E - 14$	0.081 ± 0.002	3851 ± 366	
9	Mca-ERGETGPA-Dnp	56.7	1 ± 0.7	1.62E-12	$\pm 5.20E - 14$	0.141 ± 0.004	2483 ± 58	
10	Mca-ERGETGPAG-Dn	o 43.0	$) \pm 3.8$	1.39E-12	$\pm 8.41E - 14$	0.121 ± 0.007	2810 ± 149	
11	Mca-ERGETGPAGG -	Önp 37.1	± 1.1	9.05E-13	$\pm 2.69E - 12$	0.079 ± 0.004	2120 ± 35	
12	Mca-DSGETGP-Dnp	39.6	5 ± 29.7	3.88E-14	$\pm 8.11E - 15$	0.003 ± 0.001	85 ± 60	
13	Mca-DSGETGPA-Dnp	20.2	2 ± 0.5	6.74E-13	$\pm 4.65E - 14$	0.059 ± 0.004	2900 ± 221	
14	Mca-ERGETGPSG-Dnp	51.3	3 ± 1.9	3.08E-12	$\pm 1.77E - 13$	0.268 ± 0.015	5218 ± 316	

of the consensus sequence (D/E)-(K/R)-(D/E)-G-(A/G/S/T)-G-P, the expanded consensus sequence (A/D/E/P)-(K/R)-(D/ E/P)-G-(A/G/S/T/P)-G-P, in which Pro is also included in the analysis and the P6 position only included the basic amino acids K/R, and the expanded consensus sequence (D/ E)-(K/R/P)-(D/E/P)-G-(A/G/S/T/P)-G-P, in which the P7 position included only the acidic amino acids D/E and not Pro or Ala. The (D/E)-(K/R)-(D/E)-G-(A/G/S/T)-G-P sequence is cleaved by FAP three out of the four times it appears in the gelatin sequence, Table 1. Overall unique consensus sequences were found in only 13% of the total G-P cleavage sites in gelatin. However, when present, 60% of these sequences were cleaved by FAP, Table 1. The presence of this sequence, however, was not sufficient to produce FAP cleavage in the absence of proline in the P1 amino acid, thus further confirming the importance of proline in this position. Seven such sequences containing (A/D/E/ P)-(K/R/P)-(D/E/P)-G-(A/G/S/T/P)-G-(non-proline) were identified in the gelatin sequence, and none of these were cleaved by FAP (Table 1). These results demonstrate that the frequent appearance of the (D/E)-(K/R)-(D/E)-G-(A/G/S/T)-G-P sequence in the cleavage fragments is not due to the frequent occurrence of this motif in the overall gelatin sequence, but is rather due to FAP preference for cleavage after this consensus site.

FAP Hydrolysis of Fluorescence-Quenched Peptides Based on the Gelatin Cleavage Map. While previous studies had already determined that FAP preferred to cleave after the dipeptide GP, the normalized ion current analysis also suggested a strong preference for cleavage after GP as well as a strong preference for cleavage of the peptide with GP in P2-P1 and Ala in P'1. To determine whether this type of cleavage site ranking based on the abundance of each extracted ion in the MS spectra would help predict which sequences represented good FAP substrates, we proceeded to synthesize a series of fluorescently quenched peptide substrates based on the cleavage sequences. For this analysis, we generated peptide substrate from sequences with high (i.e., ASGPAGPA, DRGETGPA), intermediate (i.e., EKGES-GP, VGPAGK), and low (i.e., GARGQAG, APGSKGDA) extracted ion currents, Figure 4. Michaelis-Menten kinetic parameters (i.e., K_m , V_{max} , k_{cat}) of FAP hydrolysis of these

fluorescence-quenched peptides were determined. $k_{\text{cat}}/K_{\text{m}}$ ratios were calculated to rank these peptides as FAP substrates (Table 2).

The Mca-ASGPAGPA-Dnp substrate (1) had the highest $k_{\text{cat}}/K_{\text{m}}$ ratio (Table 2). This peptide sequence was also based on a cleavage fragment with the second highest extracted ion current. Substrate 2, based on the fragment with the fifth ranked extracted ion current, had the second highest k_{cat}/K_m ratio. In addition, the Mca-DRGETGPA-Dnp substrate (3) had the third highest ratio. This substrate is based on a consensus sequence that is the second most common cleavage site in the map and which is found in cleavage fragments with the third, fourth, and seventh highest extracted ion currents. In contrast, the Mca-APGSKGDA-Dnp substrate (6), which was least efficiently cleaved by FAP, was based on the cleavage fragment with the lowest overall extracted ion current (Figure 4). Formal kinetic studies were not performed on a second substrate, Mca-GARGQAG-Dnp, based on the fragment with the 47th ranked extracted ion current, but this substrate demonstrated a low hydrolysis rate compared to rates from an equimolar concentration (i.e., 200 μ M) of substrates 1–5. Two other substrates with intermediate K_{cat}/K_m ratios [i.e., Mca-VGPAGK-Dnp (4) and Mca-DKGESGPA-Dnp (5)] were found in cleavage fragments with intermediate extracted ion currents (Table 2).

In a final set of studies, we synthesized additional fluorescence-quenched peptides to explore the importance of amino acids in the P' positions on the carboxy terminal side of the cleavage site (Table 3). A comparison of the K_{cat} $K_{\rm m}$ ratios of substrate 7 with no P'1 amino acid to 8 and substrate 12 to 13 demonstrated that FAP prefers an amino acid in the P'1 position. Both substrates lacking the P'1 alanine were poorly hydrolyzed by FAP. The addition of a P'2 Gly as in 10 or a P'3 Gly as in substrate 11 did not substantially improve the kinetic ratio. Other comparisons demonstrated a slight preference for Asp in the P7 position as in substrate 8 compared to Glu as in substrate 9. In the P6 position, substitution of Ser as in substrate 13 for Arg as in substrate 8 resulted in some decrease in the kinetic ratio. Finally, in the P'1 position, while Ser was only observed in 12% of the sequences compared to 47% for Ala, the substitution of Ser in the P'1 position as in substrate 14 resulted in a substantial increase in the $k_{\text{cat}}/K_{\text{m}}$ ratio compared to that of the comparable substrate **10** containing Ala in this position (Table 3). The substitution of Ser in the P'1 position generated a peptide substrate with a k_{cat} that was 2–5 fold higher than that of other active substrates.

DISCUSSION

The overall goal of this study was to develop a method to identify substrates on the basis of FAP's collagenase or gelatinase activity. This knowledge of substrate specificity can be used to elucidate FAP's biological role as well as for development of targeted therapeutic prodrugs. Substrate specificity can be defined by using either by high-throughput methods such as the positional scanning synthetic combinatorial library (15) and one-bead one-peptide library (23) or phage display (24, 25). However, these methods have the disadvantage of an artificial scaffold which can alter the physiological substrate specificity of a protease. Here we have described an approach to take a known protein substrate for a protease and map its cleavage site using proteomics. In the case of FAP, the problem was more complicated because of the polymeric nature of the collagen I protein coupled with multiple types of post-translational modifications.

A large number of collagenases and gelatinases have been previously reported in the literature. However, for most of them substrate characterization was done using combinatorial libraries or synthetic model substrates (24, 26-29). To our knowledge there is only one prior reported study in which the collagen protein was digested with a new type of collagenase and cleavage sites determined by Edman sequencing of specific bands isolated on SDS-PAGE (30). However, in this previous study only 10-12 cleavage fragments were obtained. Thus, it was possible to easily separate them by SDS-PAGE (30). In contrast, in our study the FAP digest of collagen or gelatin produced more than 100 fragments, which produced a smear on SDS-PAGE, rather than discrete bands. This result suggested that FAP cleaved collagen at many sites, thus making traditional Edman sequencing impractical. On this basis, we proceeded to develop the LC/MS/MS-based approach to map these FAP cleavage sites.

Denatured human collagen I was digested with FAP, and small size fragments (<3 kDa) were purified for MALDI-TOF analysis. Previously, MADLI-TOF has been used to identify proteins by analysis of tryptic digests (31). Mass spectra revealed that FAP was cleaving collagen I at specific sites. However, sites could not be identified by MALDI-TOF because each mass peak frequently matched more than 10 individual sequences within the collagen I protein. An attempt was also made to perform an LC/tandem MS/MS analysis on these fragments. However, the mass spectroscopic data could not be solved because of collagen's several posttranslational modifications (PTMs) that include proline hydroxylation, glycosylation, and cross-linking. Many of these PTMs have not been characterized within collagen I, and therefore, we determined that nonrecombinant, purified human collagen I could not be easily used for such an analysis.

To solve these problems, we identified a source of recombinant gelatin derived from human collagen I that had

no PTMs and which could be used for FAP cleavage mapping (22). After validating the LC/MS based method using the 8.5 kDa gelatin fragment, we proceeded to generate the map of all FAP cleavage sites within full-length 100 kDa human collagen I derived gelatin. Sequence analysis of the 51 peptide fragments from this digest confirmed earlier reported studies documenting that FAP has a preference for the dipeptide GP in the P2–P1 position. However, these earlier studies, based on a positional scanning method, reported a strict requirement for G-P for FAP hydrolysis. In contrast to these results, we documented that, while FAP prefers cleavage after the G-P dipeptide, FAP can also cleave peptides containing other amino acids in the P1 position (i.e., Ala, Arg, Asp, Gly, Glu, Lys, Ser, and Val).

One disadvantage of the positional scanning synthetic approach is that it often does not yield much specific sequence information beyond the P2–P3 position of the peptide. For the case of FAP, Edosada et al., using positional scanning, documented a preference for Ser or Ala in the P3 position (*32*). This finding also emerged from our cleavage map analysis, in which Ser/Thr was observed in 24% of the sequences in P3 and Ala was observed in 11%. In the study of Edosada et al., no preference could be observed in P4 (*32*). Using a map of a known protein substrate, in this case, allowed us to obtain additional sequence information beyond P3, with sequence preferences emerging for P4, P6, and P7 from the analysis of the cleavage map.

An added advantage of this LC/MS/MS sequencing approach is that it allowed us to quantify the abundance of each identified peptide by comparing the extracted ion current for each of the observed peptide parent ions from the MS spectra. The contribution of each parent ion to the total ion current could then be extracted and integrated over the peptide elution peak. This approach allowed us to rank the peptide fragments on the basis of the extracted ion current. Traditional Edman sequencing does not provide the potential for such fragment stratification. While it was already known before this study that FAP preferred cleavage after proline, this information could also have been learned initially from analysis of the cleavage fragments ranked by the extracted ion current.

Since the abundance of each individual fragment depends on cleavage from two sites, the extracted ion current for each fragment represents an "average" based on the efficiency of FAP cleavage at both sites. Therefore, initially, we thought the ranking would provide no additional information beyond the prediction of a preferred amino acid in the P1 position. To evaluate the utility of this ranking based on ion abundance, we synthesized seven fluorescently quenched peptide substrates based on peptide sequences from fragments with high, intermediate, and low extracted ion currents and determined FAP hydrolysis kinetics for each. The extracted ion current rankings corresponded well with the k_{cat}/K_{m} ratios of these peptide substrates, with the highest ranked having the highest ratio, etc. Although based on a limited sample of peptide substrates, these results suggest that this method of ranking cleavage sites could be applied to the analysis of cleavage maps of other proteases with unknown substrate specificity to help identify the best substrates for further synthesis and evaluation.

In conclusion, we have used an LC/MS/MS-based method to generate a map of all FAP cleavage sites within recom-

J Aggarwal et al.

binant human collagen I derived gelatin. From this map, we identified potential consensus peptide sequences that could be used to generate FAP-selective peptide—cytotoxin prodrugs. These FAP-activated prodrugs would selectively target FAP-producing myofibroblasts within the stroma of epithelial tumors and, therefore, would represent a potential "pantumor" therapeutic agent. Further studies are under way in our laboratory to assess the efficiency and specificity of these consensus peptides for FAP hydrolysis compared to those of other proteases. In addition, we are further evaluating the role of proline hydroxylation of some of these substrates to determine whether such modification enhances FAP hydrolysis.

ACKNOWLEDGMENT

We acknowledge the Mass Spectrometry/Proteomics Facility at the Johns Hopkins University School of Medicine (www.hopkinsmedicine.org/msf/) for assistance with MALDI-TOF analyses and Dr. John Isaacs for helpful comments related to preparation of the manuscript.

REFERENCES

- Dvorak, H. F. (1986) Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing, *N. Engl. J. Med.* 315, 1650–1659.
- Liotta, L. A., Steeg, P. S., and Stetler-Stevenson, W. G. (1991) Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation, *Cell* 64, 327–336.
- Basset, P., Bellocq, J. P., Wolf, C., Stoll, I., Hutin, P., Limacher, J. M., Podhajcer, O. L., Chenard, M. P., Rio, M. C., and Chambon, P. (1990) A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas, *Nature 348*, 699– 704.
- Brown, L. F., Guidi, A. J., Schnitt, S. J., Van De Water, L., Iruela-Arispe, M. L., Yeo, T. K., Tognazzi, K., and Dvorak, H. F. (1999) Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast, *Clin. Cancer Res.* 5, 1041–1056.
- Haslam, S. Z., and Woodward, T. L. (2003) Host microenvironment in breast cancer development: epithelial-cellstromal-cell interactions and steroid hormone action in normal and cancerous mammary gland, *Breast Cancer Res.* 5, 208– 215.
- Iozzo, R. V. (1995) Tumor stroma as a regulator of neoplastic behavior. Agonistic and antagonistic elements embedded in the same connective tissue, *Lab. Invest.* 73, 157–160.
- Garin-Chesa, P., Old, L. J., and Rettig, W. J. (1990) Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers, *Proc. Natl. Acad. Sci. U.S.A.* 87, 7235–7239.
- Aoyama, A., and Chen, W. T. (1990) A 170-kDa membrane-bound protease is associated with the expression of invasiveness by human malignant melanoma cells, *Proc. Natl. Acad. Sci. U.S.A.* 87, 8296–8300
- Rettig, W. J., Garin-Chesa, P., Beresford, H. R., Oettgen, H. F., Melamed, M. R., and Old, L. J. (1988) Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells, *Proc. Natl. Acad. Sci. U.S.A.* 85, 3110–3114.
- Scanlan, M. J., Raj, B. K., Calvo, B., Garin-Chesa, P., Sanz-Moncasi, M. P., Healey, J. H., Old, L. J., and Rettig, W. J. (1994) Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers, *Proc. Natl. Acad. Sci. U.S.A. 91*, 5657–61.
- Kelly, T. (2005) Fibroblast activation protein-alpha and dipeptidyl peptidase IV (CD26): cell-surface proteases that activate cell signaling and are potential targets for cancer therapy, *Drug Resist. Updates* 8, 51–8.
- Park, J. E., Lenter, M. C., Zimmermann, R. N., Garin-Chesa, P., Old, L. J., and Rettig, W. J. (1999) Fibroblast activation protein,

a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts, *J. Biol. Chem.* 274, 36505-36512.

- Denmeade, S. R., Nagy, A., Gao, J., Lilja, H., Schally, A., and Isaacs, J. (1998) Enzymatic activation of a doxorubicinpeptide prodrug by prostate-specific antigen, *Cancer Res.* 58, 2537–2540.
- 14. Denmeade, S. R., Jakobsen, C. M., Janssen, S., Khan, S. R., Garrett, E. S., Lilja, H., Christensen, S. B., and Isaacs, J. T. (2003) Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer, *J. Natl. Cancer Inst.* 95, 990– 1000.
- 15. Janssen, S., Jakobsen, C. M., Rosen, D. M., Ricklis, R. M., Reineke, U., Christensen, S. B., Lilja, H., and Denmeade, S. R. (2004) Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer, *Mol. Cancer Ther.* 3, 1439–50.
- 16. Janssen, S., Rosen, D. M., Ricklis, R. M., Dionne, C. A., Lilja, H., Christensen, S. B., Isaacs, J. T., and Denmeade, S. R. (2006) Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug, *Prostate 66*, 358–68.
- Mhaka, A., Gady, A. M., Rosen, D. M., Lo, K. M., Gillies, S. D., and Denmeade, S. R. (2004) Use of methotrexate-based peptide substrates to characterize the substrate specificity of prostatespecific membrane antigen (PSMA), *Cancer Biol. Ther.* 3, 551– 8.
- Sun, S., Albright, C. F., Fish, B. H., George, H. J., Selling, B. H., Hollis, G. F., and Wynn, R. (2002) Expression, purification, and kinetic characterization of full-length human fibroblast activation protein, *Protein Expr. Purif.* 24, 274–281.
- Piñeiro-Sánchez, M. L., Goldstein, L. A., Dodt, J., Howard, L., Yeh, Y., Tran, H., Argraves, W. S., and Chen, W. T. (1997) Identification of the 170-kDa melanoma membrane-bound gelatinase (seprase) as a serine integral membrane protease, *J. Biol. Chem.* 272, 7595–601.
- Christiansen, V. J., Jackson, K. W., Lee, K. N., and McKee, P. A. (2007) Effect of fibroblast activation protein and alpha2-antiplasmin cleaving enzyme on collagen types I, III, and IV, *Arch. Biochem. Biophys.* 457, 177–86.
- Bulleid, N. J., John, D. C., and Kadler, K. E. (2000) Recombinant expression systems for the production of collagen, *Biochem. Soc. Trans.* 28, 350–353.
- 22. Olsen, D., Jiang, J., Chang, R., Duffy, R., Sakaguchi, M., Leigh, S., Lundgard, R., Ju, J., Buschman, F., Truong-Le, V., Pham, B., and Polarek, J. W. (2005) Expression and characterization of a low molecular weight recombinant human gelatin: development of a substitute for animalderived gelatin with superior features, *Protein Expr. Purif.* 40, 346–357.
- Backes, B. J., Harris, J. L., Leonetti, F., Craik, C. S., and Ellman, J. A. (2000) Synthesis of positional-scanning libraries of fluorogenic peptide substrates to define the extended substrate specificity of plasmin and thrombin, *Nat. Biotechnol.* 18, 187– 193.
- 24. Deng, S. J., Bickett, D. M., Mitchell, J. L., Lambert, M. H., Blackburn, R. K., Carter, H. L., Neugebauer, J., Pahel, G., Weiner, M. P., and Moss, M. L. (2000) Substrate specificity of human collagenase 3 assessed using a phage-displayed peptide library, *J. Biol. Chem.* 275, 31422–31427.
- Matthews, D. J., and Wells, J. A. (1993) Substrate phage: selection of protease substrates by monovalent phage display, *Science 260*, 1113–1117.
- Knauper, V., Lopez-Otin, C., Smith, B., Knight, G., and Murphy, G. (1996) Biochemical characterization of human collagenase-3, *J. Biol. Chem.* 271, 1544–1550.
- 27. McGeehan, G. M., Bickett, D. M., Green, M., Kassel, D., Wiseman, J. S., and Berman, J. (1994) Characterization of the peptide substrate specificities of interstitial collagenase and 92kDa gelatinase. Implications for substrate optimization, *J. Biol. Chem.* 269, 32814–32820.
- Matsushita, O., Yoshihara, K., Katayama, S., Minami, J., and Okabe, A. (1994) Purification and characterization of Clostridium perfringens 120-kilodalton collagenase and nucleotide sequence of the corresponding gene, *J. Bacteriol.* 176, 149– 156.
- 29. Hori, H., and Nagai, Y. (1979) Purification of tadpole collagenase and characterization using collagen and synthetic substrates, *Biochim. Biophys. Acta* 566, 211–221.

Biochemistry

- Tsu, C. A., Perona, J. J., Schellenberger, V., Turck, C. W., and Craik, C. S. (1994) The substrate specificity of Uca pugilator collagenolytic serine protease 1 correlates with the bovine type I collagen cleavage sites, *J. Biol. Chem.* 269, 19565–19572.
 Patterson, S. D., and Aebersold, R. (1995) Mass spectrometric
- Patterson, S. D., and Aebersold, R. (1995) Mass spectrometric approaches for the identification of gel-separated proteins, *Electrophoresis* 16, 1791–1814.

FAP Substrates Identified from a Gelatin Cleavage Map K

 Edosada, C. Y., Quan, C., Wiesmann, C., Tran, T., Sutherlin, D., Reynolds, M., Elliott, J. M., Raab, H., Fairbrother, W., and Wolf, B. B. (2006) Selective inhibition of fibroblast activation protein protease based on dipeptide substrate specificity, *J. Biol. Chem.* 281, 7437–7444.

BI701921B